arrow
M

Margaret E. Gatti-Mays

the ohio state university comprehensive cancer center
H指数:23
被引数:2,719

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer

Oncotype DX风险分层和化疗接受情况对微小淋巴结阴性HR+乳腺癌患者生存结局的影响

2026-07-150
OAAI
Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer

三模态疗法与单纯化疗相比,在转移性炎性乳腺癌患者中与更高的总生存期相关。

2025-12-160
PRE
Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis

低激素受体表达对非转移性HER2阴性乳腺癌新辅助化疗反应及治疗模式的影响:一项美国国家癌症数据库分析

2025-06-090
OA
Changes in Glucose level During Chemotherapy Treatment in Patients With Stage I–IV Breast Cancer

化疗期间不同阶段(I–IV期)乳腺癌患者血糖水平的变化

2025-05-270
PRE
Chemotherapy-induced gut microbiome disruption, inflammation, and cognitive decline in female patients with breast cancer
2024-08-012
PRE
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study (vol 15, 2691, 2024)
2024-05-100
OAAI
OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)
2024-05-020
PRE
Novel Metrics of HER2 Heterogeneity in HER2Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling
2024-05-020
PRE
A Single Arm Phase 2 Study of Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Hormone Receptor-Negative, HER2Negative Early Stage/Resectable Breast Cancer
2024-05-020
PRE
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
2024-03-274
OAAI
Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines
2024-03-220
PRE